Acute myocardial infarction in an untreated patient with acute myeloid leukemia.

Autor: Kamoga D; Department of Internal Medicine White River Health Batesville Arkansas USA., Desikan S; MD Anderson Cancer Center Houston Texas USA., Desikan R; Department of Hematology/Oncology White River Health Batesville Arkansas USA., Musuuza J; Department of Internal Medicine White River Health Batesville Arkansas USA.
Jazyk: angličtina
Zdroj: Clinical case reports [Clin Case Rep] 2024 Mar 13; Vol. 12 (3), pp. e8601. Date of Electronic Publication: 2024 Mar 13 (Print Publication: 2024).
DOI: 10.1002/ccr3.8601
Abstrakt: Key Clinical Message: Acute leukemia, particularly AML, is closely associated with thrombotic events, driven by complex factors like coagulation system changes, endothelial dysfunction, and leukemic cell interactions with the vascular system. Certain chemotherapy drugs can exacerbate the prothrombotic state. Understanding these dynamics is crucial for effective thromboprophylaxis in carefully selected patients with leukemia.
Abstract: Thrombosis is a significant complication of acute leukemia. Thrombotic events mostly occur at diagnosis or during induction therapy. Here we report the occurrence of myocardial infarction (MI) before initiation of therapy, in a patient with acute myeloid leukemia not otherwise specified (AML NOS) who had no other significant risk factors for coronary artery disease. The occurrence of MI in this patient limited the choice of induction therapy and resulted in mortality. We discuss the pathogenesis and risk factors associated with increased thrombosis in AML and advocate for risk-adapted thromboprophylaxis in this patient population.
(© 2024 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje